Analysts forecast GSK’s EPS to drop to $1.25 amid a near-total earnings collapse despite strong revenue growth.
GSK is set to report second-quarter earnings before Monday’s market open, with analysts expecting a 97.3% year-over-year decline in EPS to $1.25. The sharp contraction contrasts with a 37.4% revenue increase over the same period.
Prior-year EPS stood at $46.30, reflecting a steep drop in profitability despite robust top-line growth. The company’s guidance and CEO commentary will be closely watched for signals on future performance.
No immediate market reaction has been reported ahead of the release.